Item 9A. Controls and Procedures
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of December 31, 2023. The term “disclosure controls and procedures,” means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Based on such evaluation of our disclosure controls and procedures as of December 31, 2023, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Management’s Annual Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the company, as such term is defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act. Our internal control over financial reporting is a process designed by, or under the supervision of, our principal executive officer and principal financial officer and effected by our board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
Management assessed our internal control over financial reporting as of December 31, 2023, using the criteria established in Internal Control - Integrated Framework (2013) set forth by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on the results of its evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2023. Our independent registered public accounting firm, KPMG LLP, has issued an attestation report on the effectiveness of our internal control over financial reporting, which is included in Item 8 of this Annual Report.
Changes in Internal Control Over Financial Reporting
As previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 28, 2023, we identified a material weakness in our internal control over financial reporting. The material weakness related to a deficiency in the design of a control in our revenue process to determine whether performance milestones in a newly executed drug discovery arrangement were probable of achievement and the constraint on variable consideration in the form of milestone payments can be removed. The deficiency was a result of ineffective risk assessment, as our then-existing controls were designed insufficiently to identify a change in timing of performance milestones in the newly executed contract. This material weakness resulted in a $1.7 million understatement of drug discovery revenue and a related understatement of contract assets that were corrected prior to the issuance of our consolidated financial statements as of and for the year ended December 31, 2022.
During the year ended December 31, 2023, we implemented measures designed to improve our internal control over financial reporting to remediate this material weakness, including redesigning our controls and procedures in our revenue process in order to timely identify changes to the timing of when a performance milestone becomes probable of achievement in drug discovery arrangements and to ensure such determinations are made through the end of the reporting
140
Table of Contents
period. We have redesigned the existing control to adjust the timing of performance to ensure all milestones in newly executed discovery arrangements are considered for their impact on revenue.
Based on the remediation actions taken and completed during 2023, and our testing and evaluation of the newly implemented control activities and our internal control over financial reporting, we have concluded that the material weakness has been remediated as of December 31, 2023.
Except with respect to the changes in connection with our implementation of the remediation efforts described above, there has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fourth quarter of 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations of Internal Controls
Our management, including our principal executive officer and principal financial officer, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud due to inherent limitations of internal controls. Because of such limitations, there is risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting or disclosure controls and procedures. However, these inherent limitations are known features of the disclosure and financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.
Item 9B. Other Information.
(b) Director and Officer Trading Arrangements
A significant portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or our other securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.
Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
141
Table of Contents
The following table describes, for the fourth quarter of 2023, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement , or (2) a “ non-Rule 10b5-1 trading arrangement ” (as defined in Item 408(c) of Regulation S-K):
Name and Title Action Taken (Date of Action) Type of Trading Arrangement Nature of Trading Arrangement Duration of Trading Arrangement Aggregate Number of Shares of Common Stock
Robert Abel Executive Vice President, Chief Science Officer, Platform
Adoption
( November 6, 2023 )
Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares
Sale
Until December 31, 2024, or such earlier date upon which all transactions are completed or expire without execution
Up to 48,772 shares
Margaret Dugan , Chief Medical Officer
Adoption
( November 13, 2023 )
Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be granted
Sale
Until final settlement of any covered RSU
Indeterminable (1)
Geoffrey Porges , Executive Vice President, Chief Financial Officer
Adoption
( November 28, 2023 )
Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares
Sale
Until December 6, 2024, or such earlier date upon which all transactions are completed or expire without execution
Up to 23,946 shares
(1) The number of shares subject to covered RSUs that will be sold to satisfy applicable tax withholding obligations upon vesting is unknown as the number will vary based on the extent to which vesting conditions are satisfied, the market price of our common stock at the time of settlement and the potential future grant of additional RSUs subject to this arrangement. This trading arrangement, which applies to RSUs whether vesting is based on the passage of time and/or the achievement of performance goals, provides for the automatic sale of shares that would otherwise be issuable on each settlement date of a covered RSU in an amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to us in satisfaction of the applicable withholding obligation.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not Applicable.
142
Table of Contents
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
The information required by this Item 10 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December 31, 2023 pursuant to General Instruction G(3) of Form 10-K.
We have adopted a written code of business conduct and ethics that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of the code on our website, www.schrodinger.com. In addition, we intend to post on our website all disclosures that are required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code. Our website is not incorporated by reference into this Annual Report and you should not consider any information contained in or accessible from our website to be a part of this Annual Report.
Item 11. Executive Compensation.
The information required by this Item 11 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December 31, 2023 pursuant to General Instruction G(3) of Form 10-K.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this Item 12 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December 31, 2023 pursuant to General Instruction G(3) of Form 10-K.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
The information required by this Item 13 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December 31, 2023 pursuant to General Instruction G(3) of Form 10-K.
Item 14. Principal Accountant Fees and Services.
The information required by this Item 14 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December 31, 2023 pursuant to General Instruction G(3) of Form 10-K.
143
Table of Contents
PART IV
Item 15. Exhibits and Financial Statement Schedules.
(1) Financial Statements
The following documents are included on page s F-2 through F-11 att ached hereto and are filed as part of this Annual Report.
Page
Reports of Independent Registered Public Accounting Firm
F- 2
Consolidated Balance Sheets as of December 31, 202 3 and 202 2
F- 5
Consolidated Statements of Operations for the Years ended December 31, 2023, 2022, and 2021
F- 6
Consolidated Statements of Comprehensive Income (Loss) for the Years ended December 31, 2023, 2022, and 202 1
F- 7
Consolidated Statements of Stockholders’ Equity for the Years ended December 31, 202 3 , 202 2 , and 202 1
F- 8
Consolidated Statements of Cash Flows for the Years ended December 31, 202 3 , 202 2 , and 202 1
F- 9
Notes to Consolidated Financial Statements
F- 10
(2) Financial Statement Schedules
All financial statement schedules have been omitted because they are not applicable, not required, or the information required is shown in the consolidated financial statements or the notes thereto.
(3) Exhibits
The exhibits filed as part of this Annual Report are listed below.
Exhibit
Number Description of Exhibit Form File No. Exhibit Filing Date Filed Herewith
3.1 Restated Certificate of Incorporation
8-K 001-39206 3.1 2/10/2020
3.2 Amended and Restated Bylaws of Schrödinger, Inc.
8-K 001-39206 3.1 4/13/2023
4.1 Specimen Stock Certificate evidencing the shares of common stock
S-1/A 333-235890 4.1 1/27/2020
4.2 Amended and Restated Share Exchange Agreement, dated January 24, 2020, by and between the Registrant and Bill & Melinda Gates Foundation Trust
S-1/A 333-235890 4.2 1/27/2020
4.3 Description of Securities Registered Under Section 12 of the Exchange Act
10-K 001-39206 4.3 3/4/2021
10.1 Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and among the Registrant and the other parties thereto, as amended
X
10.2+ 2010 Stock Plan, as amended
S-1 333-235890 10.2 1/10/2020
10.3+ Form of Notice of Stock Option Grant and Stock Option Agreement under 2010 Stock Plan
S-1 333-235890 10.3 1/10/2020
10.4+ 2020 Equity Incentive Plan
S-1/A 333-235890 10.4 1/27/2020
10.5+ Form of Stock Option Agreement and Form of Restricted Stock Unit Agreement for U.S. Participants under the 2020 Equity Incentive Plan
10-K 001-39206 10.5 2/24/2022
144
Table of Contents
10.6+ Form of Stock Option Agreement for Non-U.S. Participants under the 2020 Equity Incentive Plan
10-Q 001-39206 10.2 11/12/2020
10.7+ Form of Restricted Stock Unit Agreement for Non-U.S. Participants under the 2020 Equity Incentive Plan
10-K 001-39206 10.6 2/24/2022
10.8+ 2020 Employee Stock Purchase Plan
S-1/A 333-235890 10.6 1/27/2020
10.9+ Fourth Amended and Restated Director Compensation Policy
10-Q 001-39206 10.3 5/4/2023
10.10+ Senior Executive Incentive Compensation Plan
S-1 333-235890 10.8 1/10/2020
10.11+ Amended and Restated Executive Severance and Change in Control Benefits Plan, as amended
8-K 001-39206 10.2 8/18/2022
10.12+ Employment Agreement, dated May 11, 2010, by and between the Registrant and Ramy Farid
S-1 333-235890 10.10 1/10/2020
10.13+ Employment Agreement, dated August 16, 2022, by and between the Registrant and Geoffrey Porges
8-K 001-39206 10.1 8/18/2022
10.14+
Employment Agreement, dated March 17, 2003, by and between the Registrant and Jenny Herman
10-K
001-39206 10.15
2/28/2023
10.15+ Employment Agreement, dated May 14, 2018, by and between the Registrant and Karen Akinsanya
S-1 333-235890 10.14 1/10/2020
10.16+ Employment Agreement, dated April 27, 2010, by and between the Registrant and Yvonne Tran
S-1 333-235890 10.16 1/10/2020
10.17+ Employment Agreement, dated September 11, 2006, by and between the Registrant and Patrick Lorton
S-1 333-235890 10.17 1/10/2020
10.18+
Employment Agreement, dated March 9, 2009, by and between the Registrant and Robert Abel
S-1 333-235890 10.19 1/10/2020
10.19+
E mployment Agreemen t, dated July 28, 2023, by and between the Re g i strant and Margaret Dugan
X
10.20+
Consultant Agreement, dated July 1, 1999, between the Registrant and Richard A. Friesner, as amended
10-Q 001-39206 10.1 8/2/2023
10.21+ Form of Indemnification Agreement between the Registrant and each of its Executive Officers and Directors
S-1 333-235890 10.21 1/10/2020
10.22 Office Lease Agreement, dated April 5, 2021, by and between the Registrant and SPUSV5 1540 Broadway, LLC
8-K 001-39206 10.1 4/8/2021
10.23 First Amendment to Lease, dated May 19, 2022, by and between the Registrant and SPUSV5 1540 Broadway, LLC
10-Q 001-39206 10.1 8/4/2022
10.24 Lease, dated August 6, 2008, between One Main Place Portland – Oregon, Inc., Landlord, and Registrant, Tenant, as amended
S-1 333-235890 10.23 1/10/2020
10.25 Office Lease Amendment, dated May 6, 2021, by and between Registrant and MADISON-OFC ONE MAIN PLACE OR LLC
10-Q 001-39206 10.2 8/12/2021
10.26†
Agreement, dated as of May 5, 1994, between The Trustees of Columbia University in the City of New York and Registrant, as amended
S-1 333-235890 10.24 1/10/2020
10.27†
Agreement, dated as of July 15, 1998, between The Trustees of Columbia University in the City of New York and Registrant, as amended
S-1 333-235890 10.25 1/10/2020
145
Table of Contents
10.28†
Agreement, dated as of September 2001, between The Trustees of Columbia University in the City of New York and Schrödinger, LLC, as amended
S-1 333-235890 10.26 1/10/2020
10.29†
Agreement, dated as of June 19, 2003, between The Trustees of Columbia University in the City of New York and Schrödinger, LLC
S-1 333-235890 10.27 1/10/2020
10.30†
Software and Patent License Agreement, dated May 27, 2008, between The Trustees of Columbia University in the City of New York and Schrödinger, LLC
S-1 333-235890 10.28 1/10/2020
10.31†
Services Royalty Amendment, dated November 1, 2008, by and between The Trustees of Columbia University in the City of New York and Schrödinger, LLC
S-1 333-235890 10.29 1/10/2020
10.32+ Global Bonus Plan
S-1/A 333-235890 10.33 1/27/2020
10.33†
Independent Contractor Agreement, dated June 23, 2020, by and between the Registrant and Gates Ventures, LLC
10-Q 001-39206 10.2 8/10/2020
10.34†
Amendment #1 to the Independent Contractor Agreement, dated August 14, 2023, by and between the Registrant and Gates Ventures, LLC
10-Q
001-39206 10.1 11/1/2023
10.35†
Collaboration and License Agreement, dated November 22, 2020, by and between the Registrant and Bristol-Myers Squibb Company
10-K 001-39206 10.37 3/4/2021
10.36†
First Amendment to Collaboration and License Agreement, dated December 21, 2022, by and between the Registrant and Bristol-Myers Squibb Company
10-K
001-39206 10.40 2/28/2023
10.37+ 2021 Inducement Equity Incentive Plan, as amended
10-Q 001-39206 10.4 11/3/2022
10.38+ Nonstatutory Stock Option Agreement under 2021 Inducement Equity Incentive Plan
10-K 001-39206 10.39 3/4/2021
10.39+
Form of Option Agreement for Non-U.S. Participants under the 2021 Inducement Equity Incentive Plan
10-Q 001-39206 10.3 8/4/2022
10.40+ Form of Restricted Stock Unit Agreement for U.S. Participants under 2021 Inducement Equity Incentive Plan
10-Q
001-39206 10.1 5/4/2023
10.41+ Form of Restricted Stock Unit Agreement for Non-U.S. Participants under 2021 Inducement Equity Incentive Plan
10-Q
001-39206 10.2 5/4/2023
10.42+
Schrödinger, Inc. 2022 Equity Incentive Plan
8-K 001-39206 99.1 6/16/2022
10.43+
Form of Option Agreement for U.S. Participants under the 2022 Equity Incentive Plan
10-Q 001-39206 10.4 8/4/2022
10.44+
Form of Option Agreement for Non-U.S. Participants under the 2022 Equity Incentive Plan
10-Q 001-39206 10.5 8/4/2022
10.45+
Form of Restricted Stock Unit Agreement for U.S. Participants under the 2022 Equity Incentive Plan
10-Q 001-39206 10.6 8/4/2022
10.46+
Form of Restricted Stock Unit Agreement for Non-U.S. Participants under the 2022 Equity Incentive Plan
10-Q 001-39206 10.7 8/4/2022
10.47+ Sales Agreement, dated as of May 24, 2023, by and between the Registrant and SVB Securities LLC
8-K
001-39206 1.1 5/24/2023
146
Table of Contents
21.1 Subsidiaries of the Registrant
10-K
001-39206 21.1 2/28/2023
23.1 Consent of KPMG LLP, independent registered public accounting firm
X
31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
X
31.2 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
X
32.1# Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
X
32.2# Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
X
97.1+ Schrödinger , Inc . Clawback Policy
X
101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. X
101.SCH Inline XBRL Taxonomy Extension Schema Document. X
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document X
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. X
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. X
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document X
104 Cover page formatted as Inline XBRL and contained in Exhibit 101. X
† Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
# The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Schrödinger, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.
+ Management contract or compensatory plan or arrangement filed in response to Item 15(a)(3) of the Instructions to the Annual Report on Form 10-K.
Item 16. Form 10-K Summary
None.
147
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized .
SCHRÖDINGER, INC.
Date: February 28, 2024
By: /s/ Ramy Farid
Ramy Farid, Ph.D.
President and Chief Executive Officer
148
Table of Contents
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
Name Title Date
/s/ Ramy Farid President and Chief Executive Officer, Director February 28, 2024
Ramy Farid, Ph.D. (Principal Executive Officer)
/s/ Geoffrey Porges, MBBS Executive Vice President and Chief Financial Officer February 28, 2024
Geoffrey Porges (Principal Financial Officer)
/s/ Jenny Herman Senior Vice President, Finance and Corporate Controller February 28, 2024
Jenny Herman (Principal Accounting Officer)
/s/ Michael Lynton Chairman of the Board February 28, 2024
Michael Lynton
/s/ Jeffrey Chodakewitz Director February 28, 2024
Jeffrey Chodakewitz, M.D.
/s/ Richard Friesner Director February 28, 2024
Richard Friesner, Ph.D.
/s/ Gary Ginsberg Director February 28, 2024
Gary Ginsberg
/s/ Rosana Kapeller-Libermann Director February 28, 2024
Rosana Kapeller-Libermann, M.D., Ph.D.
/s/ Arun Oberoi Director February 28, 2024
Arun Oberoi
/s/ Gary Sender Director February 28, 2024
Gary Sender
/s/ Nancy Thornberry Director February 28, 2024
Nancy Thornberry
149